Your browser doesn't support javascript.
loading
Risk Factors Associated with the Development of Transaminitis in Oxandrolone-Treated Adult Burn Patients.
Kiracofe, Brittany; Zavala, Sarah; Gayed, Rita M; Foster, Charles J; Jones, Kendrea M; Oltrogge Pape, Kate; Hill, David M; Reger, Melissa; Porter, Kyle; Murphy, Claire V.
Afiliação
  • Kiracofe B; Department of Pharmacy, Spectrum Health, Grand Rapids, Michigan.
  • Zavala S; Department of Pharmacy, Loyola University Medical Center, Maywood, Illinois.
  • Gayed RM; Department of Pharmacy, Grady Hospital, Atlanta, Georgia.
  • Foster CJ; Department of Pharmacy, University of Colorado Hospital, Aurora, Colorado.
  • Jones KM; Department of Pharmacy Practice, University of Arkansas Medical Sciences College of Pharmacy, Little Rock, Arkansas.
  • Oltrogge Pape K; Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
  • Hill DM; Department of Pharmacy, Regional One Health, Memphis, Tennessee.
  • Reger M; Department of Pharmacy, Community Regional Medical Center, Fresno, California.
  • Porter K; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
  • Murphy CV; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio.
J Burn Care Res ; 40(4): 406-411, 2019 06 21.
Article em En | MEDLINE | ID: mdl-31220261
ABSTRACT
Oxandrolone has proven benefits in thermal burn injury and has become a standard of care. Transaminitis is the most frequent side effect of oxandrolone use, although no risk factors have been identified that increase the risk of transaminitis. The objective was to evaluate the frequency of transaminitis while on oxandrolone and to identify risk factors leading to an increased risk of transaminitis in adult burn patients. This multicenter retrospective risk factor analysis compared two patient groups with and without occurrence of transaminitis, which was detected by an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >100 mg/dL. Secondary outcomes included percentage increase from baseline for AST/ALT, length of stay, and mortality. After univariable analysis, a multivariable logistic regression analysis was performed to detect possible risk factors leading to transaminitis. A total of 309 patients were included, with transaminitis occurring in 128 patients (41.4%) after 13 (interquartile range [IQR] 8-23) days on oxandrolone. After multivariable analysis, age (odds ratio [OR] 0.91; 95% confidence interval [CI] 0.84-0.99 for a 5-year increase in age), intravenous vasopressor use (OR 1.85; 95% CI 1.05-3.27), and amiodarone use (OR 2.51; 95% CI 1.09-5.77) were independent predictors of transaminitis, controlling for TBSA%. Transaminitis was not significantly associated with length of stay or mortality after adjusting for age and TBSA%. We conclude that patients who are younger and have concurrent amiodarone or vasopressor use have the highest risk of developing oxandrolone induced transaminitis and should be monitored closely.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxandrolona / Queimaduras / Doença Hepática Induzida por Substâncias e Drogas / Transaminases / Anabolizantes Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxandrolona / Queimaduras / Doença Hepática Induzida por Substâncias e Drogas / Transaminases / Anabolizantes Idioma: En Ano de publicação: 2019 Tipo de documento: Article